Cited by 3,738PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase SignalingMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Oncogenic kinase signalling.

Blume-Jensen, Peter, Hunter, Tony·2001·Nature

DOI 10.1038/35077225

Open this paper in CoChat — free account

Abstract

Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans. Their activity is normally tightly controlled and regulated. Perturbation of PTK signalling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation. The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signalling. This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signalling in human malignancies.

Integrity signals

Registry

Crossref · 10.1038/35077225

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,487
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
STATs and Gene Regulation
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Signaling—2000 and Beyond
Hunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Self-citation

Flagged first, then by citations

Show all 93 references

Research works printed but not linked: 3

Blume-Jensen, P. & Hunter, T. in Encyclopedia of Cancer (ed. Bertino, J. R.) (Academic, San Diego, in the press).
Blume-Jensen, P. & Hunter, T. in Cancer Research - An Encyclopedic Reference (ed. Schwab, M.) (Springer, in the press).
Blume-Jensen, P. & Hunter, T. in Encyclopedia of Cancer (ed. Bertino, J. R.) (Academic, San Diego, in the press).

Sorted by citations

Items 101–200 of 1,008

Vitamin A and retinoid signaling: genomic and nongenomic effects
Al Tanoury, Z., Piskunov, A., & Rochette-Egly, C. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r030833 · Cited by 408
E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases
Qian, X., Karpova, T., Sheppard, A. M., McNally, J., & Lowy, D. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600136 · Cited by 396
The ErbB/HER receptor protein-tyrosine kinases and cancer
Roskoski, R. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.150 · Cited by 415
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth
Yang, Z.-Z., Tschopp, O., Hemmings-Mieszczak, M., Feng, J., Brodbeck, D., Perentes, E., & Hemmings, B. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302847200 · Cited by 384
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J. H., Zhou, J., & Zhang, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 388
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases
Marmor, M. D., & Yarden, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207390 · Cited by 382
Prevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers
Bao, L., Kimzey, A. L., Sauter, G., Sowadski, J. M., Lu, K. P., & Wang, D.-G. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63731-5 · Cited by 378
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G. (2006) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 378
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
Schnittger, S., Kohl, T. M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K., & Schoch, C. (2005) · Blood · doi:10.1182/blood-2005-04-1466 · Cited by 377
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3277 · Cited by 374
Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor
Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., & Schlessinger, J. (2007) · Cell · doi:10.1016/j.cell.2007.05.055 · Cited by 359
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 421
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis
Chan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21032 · Cited by 355
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0017 · Cited by 362
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T. ‐. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Möbitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 365
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 362
Genome of Rhodnius prolixus , an insect vector of Chagas disease, reveals unique adaptations to hematophagy and parasite infection
Mesquita, R. D., Vionette-Amaral, R. J., Lowenberger, C. A., Rivera-Pomar, R. V., Monteiro, F. A., Minx, P. J., Spieth, J., Carvalho, A. B., Panzera, F., Lawson, D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506226112 · Cited by 348
An overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 356
Untitled work
(2010) · PubMed Central
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B., & Liu, L.-Z. (2007) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 352
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Autophagy is a therapeutic target in anticancer drug resistance
Chen, S., Rehman, S. K., Zhang, W., Wen, A., Yao, L., & Zhang, J. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.003 · Cited by 347
Use of PET for monitoring cancer therapy and for predicting outcome.
Weber, W. (2005) · PubMed · Cited by 338
Tuberous Sclerosis: from Tubers to mTOR
Kwiatkowski, D. J. (2003) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2003.00012.x · Cited by 340
Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation
Changeux, J., & Christopoulos, A. (2016) · Cell · doi:10.1016/j.cell.2016.08.015 · Cited by 353
Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis
Zhao, X., Weir, B. A., LaFramboise, T., Lin, M. G., Beroukhim, R., Garraway, L. A., Beheshti, J., Lee, J. C., Naoki, K., Richards, W. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4603 · Cited by 337
Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21‐dependent pathway
Miyauchi, H., Minamino, T., Tateno, K., Kunieda, T., Toko, H., & Komuro, I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600045 · Cited by 335
Arsenic in the aetiology of cancer
Tapio, S., & Grosche, B. (2006) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2006.02.001 · Cited by 338
Illuminating the dark phosphoproteome
Needham, E. J., Parker, B. L., Burykin, T., James, D. E., & Humphrey, S. J. (2019) · Science Signaling · doi:10.1126/scisignal.aau8645 · Cited by 336
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan‐Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 339
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Álvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 339
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 337
Activation pathway of Src kinase reveals intermediate states as targets for drug design
Shukla, D., Meng, Y., Roux, B., & Pande, V. S. (2014) · Nature Communications · doi:10.1038/ncomms4397 · Cited by 333
A high-throughput approach for measuring temporal changes in the interactome
Kristensen, A. R., Gsponer, J., & Foster, L. J. (2012) · Nature Methods · doi:10.1038/nmeth.2131 · Cited by 331
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Munshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J. E., Moussa, M. M., Leggett, D., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 330
Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 343
Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B
Scheid, M. P., Marignani, P. A., & Woodgett, J. R. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6247-6260.2002 · Cited by 328
Juxtamembrane autoinhibition in receptor tyrosine kinases
Hubbard, S. R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1399 · Cited by 343
Regulation of the Src Family Kinases by Csk
Okada, M. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.5141 · Cited by 309
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells
Bafico, A., Liu, G., Goldin, L., Harris, V., & Aaronson, S. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.032 · Cited by 329
Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
Choudhary, C., Olsen, J. V., Brandts, C., Cox, J., Reddy, P. N. G., Böhmer, F., Gerke, V., Schmidt‐Arras, D., Berdel, W. E., Müller‐Tidow, C., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.019 · Cited by 336
KIT Mutations Are Common in Testicular Seminomas
Kemmer, K. A., Corless, C. L., Fletcher, J. A., McGreevey, L. S., Haley, A., Griffith, D., Cummings, O. W., Wait, C. L., Town, A., & Heinrich, M. C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63120-3 · Cited by 319
Proteomic and interactomic insights into the molecular basis of cell functional diversity
Bludau, I., & Aebersold, R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0231-2 · Cited by 297
TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation
Lu, Q., Hope, L. W., Brasch, M., Reinhard, C., & Cohen, S. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932599100 · Cited by 301
Molecular genetics of multiple endocrine neoplasia types 1 and 2
Marx, S. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1610 · Cited by 318
Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion
Shukla, S., MacLennan, G. T., Hartman, D. J., Fu, P., Resnick, M. I., & Gupta, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22862 · Cited by 322
Positron Emission Tomography As an Imaging Biomarker
Weber, W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6068 · Cited by 313
Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers
Zhou, X., Tan, M., Hawthorne, V. S., Klos, K. S., Lan, K., Yang, Y., Yang, W., Smith, T. L., Shi, D., & Yu, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0112 · Cited by 318
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Hierarchical mesoscale domain organization of the plasma membrane
Kusumi, A., Suzuki, K. G. N., Kasai, R. S., Ritchie, K. P., & Fujiwara, T. K. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.001 · Cited by 310
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V. M., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307
Mechanisms of drug inhibition of signalling molecules
Sebolt, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 309
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y., Fishman, D. A., Espina, V. A., Aquino, J., Speer, R., Araujo, R. P., Mills, G. B., et al. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500003-mcp200 · Cited by 306
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 335
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Kelly, L. M., Yu, J., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I. R., Amaral, S. M., Curley, D. P., Duclos, N., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00070-3 · Cited by 305
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray‐Rust, J., Kjær, S., Scott, R. P., Hanrahan, S. J., Santoro, M. M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 313
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 315
Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung
Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., Bigiani, N., Schirosi, L., Casali, C., Morandi, U., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8233 · Cited by 303
Microparticles in Cancer
Rak, J. W. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1267043 · Cited by 311
A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage
Andersen, J. N., Jansen, P. G., Echwald, S. M., Mortensen, O. H., Fukada, T., Vecchio, R. D., Tonks, N. K., & M⊘ller, N. P. H. (2004) · The FASEB Journal · doi:10.1096/fj.02-1212rev · Cited by 311
Autophagy as a therapeutic target in cancer
Chen, N., & Karantza, V. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14622 · Cited by 309
Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases
Moritz, A., Yu, L., Guo, A., Villén, J., Wang, Y., MacNeill, J., Kornhauser, J. M., Sprott, K. M., Zhou, J., Possemato, A. P., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000998 · Cited by 300
Mechanisms of hypolipidemic and anti‐obesity effects of tea and tea polyphenols
Lin, J., & Lin‐Shiau, S. (2006) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500138 · Cited by 303
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 298
An orthosteric inhibitor of the Ras-Sos interaction
Patgiri, A., Yadav, K. K., Arora, P. S., & Bar‐Sagi, D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.612 · Cited by 298
Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface
Dawson, J. P., Berger, M. B., Lin, C.-C., Schlessinger, J., Lemmon, M. A., & Ferguson, K. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7734-7742.2005 · Cited by 298
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.023 · Cited by 332
Signal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389
Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines
Callow, M. G., Clairvoyant, F., Zhu, S., Schryver, B. B., Whyte, D. B., Bischoff, J. R., Jallal, B., & Smeal, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105732200 · Cited by 291
Nuclear receptors: integration of multiple signalling pathways through phosphorylation
Rochette-Egly, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00115-8 · Cited by 291
Caveolin-1 Maintains Activated Akt in Prostate CancerCells through Scaffolding Domain Binding Site Interactions with andInhibition of Serine/Threonine Protein Phosphatases PP1 andPP2A
Li, L., Ren, C. H., Tahir, S. A., Ren, C., & Thompson, T. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9389-9404.2003 · Cited by 291
P68 RNA Helicase Mediates PDGF-Induced Epithelial Mesenchymal Transition by Displacing Axin from β-Catenin
Yang, L., Lin, C., & Liu, Z.-R. (2006) · Cell · doi:10.1016/j.cell.2006.08.036 · Cited by 299
The alphabet of intrinsic disorder
Theillet, F., Kalmár, L., Tompa, P., Han, K., Selenko, P., Dunker, A. K., Daughdrill, G. W., & Uversky, V. N. (2013) · Intrinsically Disordered Proteins · doi:10.4161/idp.24360 · Cited by 283
Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K
Kozma, S. C., & Thomas, G. (2002) · BioEssays · doi:10.1002/bies.10031 · Cited by 289
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives
Singh, R. K., Kumar, S., Prasad, D. N., & Bhardwaj, T. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.001 · Cited by 284
Large-scale Proteomics Analysis of the Human Kinome
Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R., Greff, Z., Kéri, G., Mann, M., & Daub, H. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800588-mcp200 · Cited by 285
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S. A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.332 · Cited by 286
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 288
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Smith, B. D., Kaufman, M. D., Lu, W.-P., Gupta, A., Leary, C. B., Wise, S., Rutkoski, T. J., Ahn, Y. M., Al-Ani, G., Bulfer, S. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.006 · Cited by 283
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
Brantley‐Sieders, D. M., Zhuang, G., Hicks, D. J., Fang, W. B., Hwang, Y., Cates, J., Coffman, K. T., Jackson, D., Bruckheimer, E., Muraoka-Cook, R. S., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33154 · Cited by 283
The role of Shp2 (PTPN11) in cancer
Mohi, G., & Neel, B. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.011 · Cited by 282
Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy
Asamitsu, S., Obata, S., Yu, Z., Bando, T., & Sugiyama, H. (2019) · Molecules · doi:10.3390/molecules24030429 · Cited by 280
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec
Wang, Y., Zhou, G., Yin, T., Chen, B., Shi, J.-Y., Liang, W., Jin, X.-L., You, J., Yang, G., Shen, Z., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408831102 · Cited by 276
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
Gao, N., Zhang, Z., Jiang, B., & Shi, X. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.132 · Cited by 275
Helicobacter pylori CagA Induces Ras-independent Morphogenetic Response through SHP-2 Recruitment and Activation
Higashi, H., Nakaya, A., Tsutsumi, R., Yokoyama, K., Fujii, Y., Ishikawa, S., Higuchi, M., Takahashi, A., Kurashima, Y., Teishikata, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309964200 · Cited by 273
Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation
Mol, C. D., Lim, K. B., Sridhar, V., Zou, H., Chien, E. Y. T., Sang, B., Nowakowski, J., Kassel, D. B., Cronin, C. N., & McRee, D. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300186200 · Cited by 273
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
Li, G., Robinson, G. W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, N., Wagner, K.-U., Wu, D.-C., Lane, T. F., Liu, X., et al. (2002) · Development · doi:10.1242/dev.129.17.4159 · Cited by 272
Phosphoprotein Analysis Using Antibodies Broadly Reactive against Phosphorylated Motifs
Zhang, H., Zha, X., Tan, Y., Hornbeck, P. V., Mastrangelo, A. J., Alessi, D. R., Polakiewicz, R. D., & Comb, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206399200 · Cited by 268
The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target
Zhou, X. Z., & Lu, K. P. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.49 · Cited by 275
The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Arcaro, A., & Stücklin, A. G. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 274
Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients
Zaenker, P., Gray, E. S., & Ziman, M. R. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.017 · Cited by 265
The Multifaceted Role of MTDH/AEG-1 in Cancer Progression
Hu, G., Wei, Y., & Kang, Y. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0049 · Cited by 267
Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators
Major, M. L., Lepe, R., & Costa, R. H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2649-2661.2004 · Cited by 268
Imatinib: a selective tyrosine kinase inhibitor
Manley, P. W., Cowan‐Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., & Zimmermann, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80599-8 · Cited by 272
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 272
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R. A., Moldovan, C. S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 307

Authors: Blume-Jensen, P., & Hunter, T.
Affiliations: Salk Institute for Biological Studies (US)
ORCID: Hunter, Tony
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2001-05-01
Volume: 411
Issue: 6835
Pages: 355-365
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/35077225
OpenAlex: W1639582946
Cited by: 3,738
References: 93
Citations by year: 2026: 48 · 2025: 69 · 2024: 87 · 2023: 102 · 2022: 103 · 2021: 114 · 2020: 121 · 2019: 118 · 2018: 105 · 2017: 119 · 2016: 131 · 2015: 156 · 2014: 186 · 2013: 185 · 2012: 200
FWCI: 12.95
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: tyrosine kinase, oncogenic signaling, signal transduction, phosphatidylinositol 3-kinase, Akt, p70 S6 kinase, mTOR, kinase autoinhibition, malignant transformation, human malignancies
MeSH terms: Animals, Humans, Mutation, Neoplasms, Oncogenes, Protein-Tyrosine Kinases, Signal Transduction, Oncogene Proteins, Retroviridae Proteins, Oncogenic, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, Receptor Protein-Tyrosine Kinases, Oncogene Protein v-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oncogenic kinase signalling.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks